Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2024
Reporting Period: Event date of September 26, 2024
Context: The Company is an emerging growth company incorporated in Texas, reporting a partial closing of a Securities Purchase Agreement (SPA) with an institutional accredited investor.
Key Financial Metrics and Transaction Details
This filing reports a specific equity financing event rather than periodic financial performance metrics (revenue, profit, cash flow, or margins are not disclosed in this document).
- Transaction Type: Unregistered sale of Series B Convertible Preferred Stock.
- Shares Sold: 250 shares of Series B Preferred Stock.
- Proceeds Raised: $250,000.
- Stated Value: $1,100 per share.
- Effective Purchase Price: 10% discount to the stated value.
- Remaining Availability: 250 shares of Series B Preferred Stock remain available for future sale under the Fourth Closing.
Material Changes and Conversion Terms
The filing details the progression of the Fourth Closing under the SPA, which was originally subject to conditions. As of this report, 750 of the 1,000 possible Fourth Closing shares have been sold.
- Conversion Potential: If the 250 shares sold in this transaction were converted in full (excluding in-kind dividends), they would result in a maximum of 1,833,333 shares of common stock.
- Conversion Floor Price: $0.15 per share.
- Regulatory Approval: Stockholders approved the issuance of more than 19.99% of outstanding common stock upon conversion at the June 17, 2024 Annual Meeting, in accordance with Nasdaq Listing Rule 5635(d).
Guidance, Risks, and Contingencies
Exemption Status: The issuance was exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as it did not involve a public offering and was sold to an accredited investor for investment purposes.
Transfer Restrictions: The securities are subject to transfer restrictions and contain a legend stating they have not been registered under the Securities Act and may not be offered or sold absent registration or an exemption.
Outlook: The filing does not provide forward-looking guidance, management commentary on operations, or specific risk factors beyond the standard transfer restrictions and the contingent nature of the remaining 250 shares under the SPA.
Investor Verification Checklist
- Verify the total dilution impact of the 1,833,333 potential common shares from this specific tranche against the current outstanding share count.
- Confirm the status of the remaining 250 shares of Series B Preferred Stock available under the Fourth Closing and any conditions required for their sale.
- Review the April 2024, July 2024, and August 2024 Form 8-K filings for the full rights and preferences of the Series B Preferred Stock.
- Assess the Company's cash position post-transaction, noting that $250,000 in proceeds were received on September 26, 2024.